Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Panic episodes were described as a distinct form of anxiety by Freud almost 100 years ago, and the recent publication of the Diagnostic and Statistical Manual of Mental Disorders, third edition (D.S.M.-III), has provided the basis for the separate diagnostic entity of panic disorder. In this study, we showed the historical review of research and the result of our clinical study of panic disorder in 7 patients. The following results were obtained: 1) Abnormal DSTs were observed in only two of 5 patients. 2) Five of 6 patients showed high concentration of adrenaline and noradrenaline in urine. 3) Anxiety was provoked by caffeine in two of 5 patients. 4) Depression of T-wave was shown in three of 5 patients with orthostatic E.C.G. 5) Sinus tachycardia was gained in one of 3 patients with Holter E.C.G. 6) Abnormal respiratory functions were observed in all two patients with Treadmill. 7) Only one small heart was observed on a chest radiograph. 8) Panic attacks were provoked by sodium lactate infusion in four of 7 patients.
 ...
PMID:[Panic disorder]. 128 52

187 patients were investigated by a structured interview for DSM-III-R and various clinicians' and patients' ratings. A high frequency of comorbidity between different anxiety disorders and between anxiety and depression was found. According to sociodemographic data, various anxiety disorders showed more similarities than differences. Patients with a generalized anxiety disorder showed an earlier age at onset compared to patients with panic disorder as well as a greater severity of illness and comorbidity. Avoidance behavior occurred before, simultaneous with, as well as after the onset of panic disorder.
 ...
PMID:Differentiation of DSM-III-R anxiety disorders by severity of illness and symptom onset sequences. 129 30

We looked for the present and past history of functional disorders, especially mood disorders among 215 inpatients with diagnosis of alcohol dependence using Schedule for Affective Disorders and Schizophrenia--Life-time Version (SADS-L). This same was determined in their first degree relatives using Family History--Research Diagnostic Criteria (FH--RDC). The incidence of mood disorders among probands was rather low--9.8% (bipolar--0.9%, recurrent depression--2.8%, minor depression--6.0%), the occurrence of other functional disorders was much more rare: 2 patients--panic disorder, 2--general anxiety disorders. Among first degree relatives only two had history of depression. The incidence of alcoholism was rather high, especially in men.
 ...
PMID:[Depressive syndromes in patients dependent on alcohol with regard to mental disorders in the family]. 129 7

Results of numerous community surveys of psychiatric illness suggest a striking change in the occurrence of depression, with younger generations experiencing higher lifetime risk and earlier age of onset. Data from the National Institute of Mental Health Epidemiologic Catchment Area Survey (a cross-sectional survey of psychiatric morbidity in five US communities conducted between 1980 and 1984) were reexamined for evidence of methods effects which might contribute to these unexpected findings. A pattern of higher lifetime risk and earlier age of onset among recent birth cohorts was observed for every psychiatric disorder examined, with schizophrenia, major depression, and panic disorder showing equally strong trends. For respondents of all ages, reported first onset of major depression clustered in the 10-year period prior to the study interview, in contrast to the expectation that older respondents would report onset in early adulthood. Examination of individual psychiatric symptoms revealed a nearly universal pattern of decreasing lifetime prevalence among older respondents, a reversal of the expected accumulation of lifetime symptoms with age. These findings suggest that effects of study methods may contribute to the apparent temporal trends in prevalence of depression and that cross-sectional surveys may underestimate lifetime psychiatric morbidity among older respondents. Generational changes in the lifetime risk of depression or other psychiatric disorders may not be reliably assessed by cross-sectional survey data.
 ...
PMID:Reevaluation of secular trends in depression rates. 833 21

Immunological, neuroendocrine and psychological parameters were examined in 14 psychophysically healthy subjects and in 17 panic disorder patients before and after a 30-day course of alprazolam therapy. T lymphocyte proliferation in response to the mitogen phytohemagglutinin, lymphocyte beta-endorphin (beta-EP) concentrations, plasma ACTH, cortisol and beta-EP levels were examined in basal conditions and after corticotropin-releasing hormone (CRH) stimulation. Cortisol inhibition by dexamethasone (DST) and basal growth hormone (GH) and prolactin levels were also examined. Depression, state or trait anxiety, anticipatory anxiety, agoraphobia, simple and social phobias, severity and frequency of panic attacks were monitored by rating scales. The immune study did not reveal any significant difference between patients and controls, or any effect of alprazolam therapy. The hormonal data for the two groups were similar, except for higher than normal basal ACTH and GH plasma levels, lower than normal ratios between the ACTH and cortisol responses to CRH, and blunted DST in some patients. All the impairments improved after alprazolam therapy, in parallel with decreases in anxiety and in severity and frequency of panic attacks.
 ...
PMID:Psychoimmunoendocrine aspects of panic disorder. 133 59

The authors achieve a review of some clinical and therapeutic features related to the use of azaspirodecanodiones (buspirones, gepirone, ipsapirone). Buspirone--the only one available--is a novel nonbenzodiazepine anxiolytic that shows affinity for the serotonin 1A receptor subtype, acting as a partial agonist in the serotonergic system. This review attempts to put up to date the therapeutic studies of azaspirodecanodiones--especially buspirone--in anxiety (panic disorder, generalized anxiety disorder, obsessive-compulsive disorder), depression abuse and dependence of substances and other neuropsychiatric disorders. Though its main indication is generalized anxiety disorder, it may be also useful in treating other disorders and multiple psychopathologies related to serotonergic system dysfunctions, such as depression or alcoholism. Other interesting feature of buspirone is its potential usefulness in anxious elderly patients and long-term therapy.
 ...
PMID:[Azaspirodecanodiones in clinical psychiatry]. 135 93

Selective serotonin reuptake inhibitors (SSRIs) are a recently developed class of drugs with significantly greater antidepressant efficacy than placebo. Generally, in double-blind comparative trials, all SSRIs demonstrated antidepressant efficacy similar to that of the 'standard' tricyclic antidepressants amitriptyline and imipramine; a meta-analysis of controlled trials found the efficacy of the SSRIs to be equivalent to that of the 2 tricyclics. Nevertheless, because of small patient numbers included in most studies that compare SSRIs with other antidepressants, no definitive statements about relative efficacy can be made. In these studies it is simply possible to state that no statistically significant differences were identified between SSRIs and the comparative antidepressants. Importantly, differences in clinical characteristics exist between the SSRIs-differences in elimination half-life (t1/2 beta) between fluoxetine and/or its metabolite (total t1/2 beta = 330 hours) and other SSRIs (t1/2 beta range = 15 to 30 hours), for example. This has implications in terms of potential drug interactions and must be considered when patients have to be switched to treatment with monoamine oxidase inhibitors. Studies with fluvoxamine have been conducted in both in- and outpatients, whereas trials with other SSRIs have been confined largely to outpatient populations. Fluvoxamine has been associated with a high incidence of nausea (37%), although this may have resulted from high initial dosages (rather than upward dose titration protocols) used in early trials. Of further interest, fluoxetine doses of 20mg may be sufficient to produce a satisfactory antidepressant response, and this SSRI may be particularly useful in patients with chronic retarded depression. More clinical data are required before the efficacy of sertraline and citalopram relative to standard antidepressants can be clearly defined. Preliminary data indicate that SSRIs are effective in the treatment of panic disorder, obsessive-compulsive disorder (OCD), eating (e.g. anorexia and bulimia) and personality disorders (e.g. anger, impulsiveness) and substance abuse (e.g. alcoholism); early results with fluvoxamine in the treatment of panic disorder and OCD, and with fluoxetine in the treatment of bulimia, personality disorders and alcohol abuse, have been encouraging. SSRIs have a more favourable tolerability profile than tricyclic antidepressants and, unlike the tricyclics, are not associated with anticholinergic adverse effects, sedation, cardiotoxicity or weight gain. SSRIs are associated with a relatively high incidence of nausea, particularly if high doses are used at the start of treatment. However, the incidence of nausea appears to decrease as treatment is continued.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Comparative efficacy of antidepressants. 137 69

Phenelzine (PLZ), a nonselective monoamine oxidase inhibitor, is widely used in psychiatry for the treatment of panic disorder and depression. The effects of chronic (28-day) administration of PLZ (0.05 mmol/kg/day) and its N-acetylated analogue, 1-acetyl-2-(2-phenylethyl) hydrazine (N2-acetylphenelzine; N2AcPLZ; 0.10 mmol/kg/day), on alpha 2-adrenoreceptor function were investigated by use of a behavioral test on days 21 and 22. Rats treated with PLZ or N2AcPLZ displayed a significant attenuation of the suppressant effects of clonidine on spontaneous locomotor activity, compared with controls; these results suggest a reduced sensitivity of alpha 2-adrenoreceptors. By day 28, both PLZ and N2AcPLZ had produced greater than 85% inhibition of monoamine oxidases A and B in the brain, heart, and liver. Both drugs induced significant elevations of whole-brain levels of noradrenaline, 5-hydroxytryptamine, and dopamine, compared with those in controls. The levels of acid metabolites of dopamine and 5-hydroxytryptamine (homovanillic acid, 3,4-dihydroxyphenylacetic acid, and 5-hydroxyindole-3-acetic acid) were significantly reduced in both groups of drug-treated animals.
 ...
PMID:Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function. 138 93

The response to treatment with imipramine or clonazepam was evaluated in patients with panic disorder. These patients had a high urinary 3-methoxy-4-hydroxy-phenylglycol 24 h-excretion and normal plasma lactate levels. Both drugs were efficient as anti-panic agents, but clonazepam resulted more efficacious than imipramine by the scores of Hamilton Anxiety or Depression Scales. Moreover, clonazepam also reduced the anticipatory anxiety.
 ...
PMID:[Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam]. 139 Oct 76

Positron emission tomography (PET) offers a possibility to study brain function and its relationship to psychiatric disorders. Clinical studies have demonstrated that several psychiatric diseases are coupled with changes in brain glucose metabolism. Schizophrenia seems to involve a lower metabolism in wide areas of the brain--both cortical and subcortical structures. Depression probably involves dysfunction of the metabolism in dorsolateral prefrontal cortex. Obsessive compulsive disorder, panic disorder, anorexia nervosa and the experience of anxiety may involve increased metabolic rates. The results from the different studies do not allow quantitative comparisons or detailed analyses because of large differences in experimental and clinical methodology. The term Good Clinical PET Practice (GCPP) is suggested to encourage standardization in clinical investigations. GCPP includes standardization of both experimental factors (lumped constant, arterialization, purity of tracer, regions of interest, relative rates) and clinical factors (state of the subject, wakefulness, anxiety, gender, course of the disease) in PET performance.
 ...
PMID:Glucose metabolism in psychiatric disorders: how can we facilitate comparisons among studies? 140 49


1 2 3 4 5 6 7 8 9 10 Next >>